Flare Therapeutics biochemists Yong Li (L) and Valerie Vivat
March 22, 2023 06:30 AM EDT
Financing
Startups

A $123M Flare will get Third Rock on­col­o­gy biotech in­to the clin­ic this year

Kyle LaHucik

Senior Reporter

Flare Ther­a­peu­tics will start its first hu­man tri­al this year with an in­ves­ti­ga­tion­al urothe­lial can­cer drug af­ter pulling to­geth­er a $123 mil­lion Se­ries B from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times